Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.
Nadjib HammoudiDongtak JeongRajvir SinghAhmed FarhatMichel KomajdaEric MayouxRoger HajjarDjamel LebechePublished in: Cardiovascular drugs and therapy (2018)
The data show that chronic treatment with empagliflozin improves diastolic function, preserves calcium handling and growth signaling pathways and attenuates myocardial insulin resistance in ob/ob mice, findings suggestive of a potential clinical utility for empagliflozin in the treatment of diastolic dysfunction.
Keyphrases
- left ventricular
- blood pressure
- acute myocardial infarction
- heart failure
- hypertrophic cardiomyopathy
- oxidative stress
- signaling pathway
- cardiac resynchronization therapy
- mitral valve
- metabolic syndrome
- gene expression
- type diabetes
- ejection fraction
- combination therapy
- genome wide
- adipose tissue
- acute coronary syndrome
- climate change
- epithelial mesenchymal transition
- coronary artery disease
- risk assessment
- dna methylation
- atrial fibrillation
- percutaneous coronary intervention
- artificial intelligence
- data analysis
- pi k akt